Key points
- Q1 FY25 revenue of $7.1m, up 1% vs pcp
- Underlying EBITDA of $0.1m
- ARR of $31.4m, up 16% vs pcp
Full summary
IMEXHS reported its Q1 FY25 results, with revenue of $7.1m, up 1% vs pcp, and Underlying EBITDA of $0.1m. ARR grew 16% vs pcp to $31.4m. The company secured new software contracts with Clinica del Occidente and Hospital Moncaleano, and extended an agreement with existing client Diodiagnostico. IMEXHS also made progress on its Aquila+ radiology platform, with the system now live at eight sites. The company completed a $2.5m capital raising to support growth, including a $1.5m placement and a $1.0m conditional placement to directors. A Share Purchase Plan is also underway. During the quarter, IMEXHS continued to execute on its product roadmap, delivering enhancements across the IMEXHS Cloud and Enterprise portfolio, including further optimisation of Aquila+, improvements to the Patient Portal, and upgrades to the Universal Viewer and PACS platforms.
Guidance
The company expects strong revenue growth and to be EBITDA and cash positive for 2025, with more of the growth in Revenue, Earnings and Cash occurring in H2.
Outlook
IMEXHS expects an acceleration of software sales as the Aquila+ platform is rolled out to new and existing customers. The company's Radiology Profit Improvement Program through pricing and productivity is also expected to see performance improve through the year.